REFERENCES
1. Swain SM, Baselga J, Miles D, Im YH, Quah C, et al. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann Oncol 2014;25:1116-21.
2. Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res 2011;17:4834-43.
3. Moliterni A, Mariani G, Stella GC, Mariani L, Bianchi GV, et al. Long-term results from INT-HER study: retrospective evaluation of adjuvant trastuzumab in unselected HER2-positive breast cancer patients-single institution experience. J Clin Oncol 2014;32.
4. Ow SGW, Yong YFL, Chieng WS, Phyu PS, Lee SC. Clinical outcome of HER2-positive breast cancer patients after failure on adjuvant trastuzumab: the potential of the time to relapse. Clin Oncol 2014;26:174-5.
5. Ramakrishna N, Temin S, Lin NU. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: ASCO clinical practice guideline update summary. J Oncol Pract 2018;14:505-7.
6. Ramakrishna N, Temin S, Chandarlapaty S, Crews JR, Davidson NE, et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014;32:2100-8.
7. Steeg PS, Camphausen KA, Smith QR. Brain metastases as preventive and therapeutic targets. Nat Rev Cancer 2011;11:352-63.
8. Stemmler HJ, Heinemann V. Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challenge. Oncologist 2008;13:739-50.
9. Lin NU, Carey LA, Liu MC, Younger J, Come SE, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008;26:1993-9.
10. Lin NU, Dieras V, Paul D, Lossignol D, Christodoulou C, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009;15:1452-9.
11. Yap TA, Vidal L, Adam J, Stephens P, Spicer J, et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 2010;28:3965-72.
12. Da Silva L, Simpson PT, Smart CE, Cocciardi S, Waddell N, et al. HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Res 2010;12:R46.
13. Kodack DP, Askoxylakis V, Ferraro GB, Fukumura D, Jain RK. Emerging strategies for treating brain metastases from breast cancer. Cancer Cell 2015;27:163-75.
14. Lin NU, Gelman RS, Younger WJ, Sohl J, Freedman RA, et al. Phase II trial of carboplatin (C) and bevacizumab (BEV) in patients (pts) with breast cancer brain metastases (BCBM). J Clin Oncol 2013;31.
15. Lu YS, Chen WW, Lin CH, Tseng LM, Yeh DC, et al. Bevacizumab, etoposide, and cisplatin (BEEP) in brain metastases of breast cancer progressing from radiotherapy: results of the first stage of a multicenter phase II study. J Clin Oncol 2012;30.
16. Bartsch R, Berghoff AS, Preusser M. Breast cancer brain metastases responding to primary systemic therapy with T-DM1. J Neurooncol 2014;116:205-6.
17. Krop IE, Kim SB, Gonzalez-Martin A, LoRusso PM, Ferrero JM, et al. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol 2014;15:689-99.
18. Verma S, Miles D, Gianni L, Krop IE, Welslau M, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-91.
19. Beadnell TC, Nassar KW, Rose MM, Clark EG, Danysh BP, et al. Src-mediated regulation of the PI3K pathway in advanced papillary and anaplastic thyroid cancer. Oncogenesis 2018;7:23.
20. Rexer BN, Ham AJL, Rinehart C, Hill S, Granja-Ingram ND, et al. Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. Oncogene 2011;30:4163-74.
21. Zhang SY, Huang WC, Zhang L, Zhang CY, Lowery FJ, et al. Src family kinases as novel therapeutic targets to treat breast cancer brain metastases. Cancer Res 2013;73:5764-74.
22. Du Y, Du Z, Zheng H, Wang D, Li S, et al. GABA exists as a negative regulator of cell proliferation in spermaogonial stem cells. Cell Mol Biol Lett 2013;18:149-62.
23. Young SZ, Bordey A. GABA's control of stem and cancer cell proliferation in adult neural and peripheral niches. Physiology (Bethesda) 2009;24:171-85.
24. Young SZ, Bordey A. GABA's control of stem and cancer cell proliferation in adult neural and peripheral niches. Physiology 2009;24:171-85.
25. Choy C, Ansari KI, Neman J, Hsu S, Duenas MJ, et al. Cooperation of neurotrophin receptor TrkB and Her2 in breast cancer cells facilitates brain metastases. Breast Cancer Res 2017;19:51.
26. Opdam FL, Guchelaar HJ, Beijnen JH, Schellens JH. Lapatinib for advanced or metastatic breast cancer. Oncologist 2012;17:536-42.
27. Freedman RA, Hughes ME, Ottesen RA, Weeks JC, He Y, et al. Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network. Cancer 2013;119:839-46.
28. Collins I, Francis P, Mileshkin L. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2012;366:664; author reply 664-6.
29. Chen L, Yang L, Yao L, Kuang XY, Zuo WJ, et al. Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients. Nat Commun 2018;9:1357.
30. Jensen JD, Knoop A, Laenkholm AV, Grauslund M, Jensen MB, et al. PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Ann Oncol 2012;23:2034-42.
31. Zardavas D, Te Marvelde L, Milne RL, Fumagalli D, Fountzilas G, et al. Tumor PIK3CA genotype and prognosis in early-stage breast cancer: a pooled analysis of individual patient data. J Clin Oncol 2018;36:981-90.
32. Paplomata E, O'Regan R. The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. Ther Adv Med Oncol 2014;6:154-66.
33. Abraham J. PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies? Expert Rev Anticancer Ther 2015;15:51-68.
34. Bahrami A, Khazaei M, Shahidsales S, Hassanian SM, Hasanzadeh M, et al. The therapeutic potential of PI3K/Akt/mTOR inhibitors in breast cancer: rational and progress. J Cell Biochem 2018;119:213-22.
35. Chia S, Gandhi S, Joy AA, Edwards S, Gorr M, et al. Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer. Curr Oncol 2015;22:33-48.
36. Ghayad SE, Cohen PA. Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients. Recent Pat Anticancer Drug Discov 2010;5:29-57.
37. Lee JJ, Loh K, Yap YS. PI3K/Akt/mTOR inhibitors in breast cancer. Cancer Biol Med 2015;12:342-54.
38. Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009;459:1005-9.
39. Ulasov IV, Kaverina NV, Pytel P, Thaci B, Liu F, et al. Clinical significance of KISS1 protein expression for brain invasion and metastasis. Cancer 2012;118:2096-105.
40. Neman J, Termini J, Wilczynski S, Vaidehi N, Choy C, et al. Human breast cancer metastases to the brain display GABAergic properties in the neural niche. Proc Natl Acad Sci U S A 2014;111:984-9.
41. Smits A, Jin Z, Elsir T, Pedder H, Nister M, et al. GABA-A channel subunit expression in human glioma correlates with tumor histology and clinical outcome. PLoS One 2012;7:e37041.
42. Quail DF, Joyce JA. The microenvironmental landscape of brain tumors. Cancer Cell 2017;31:326-41.
43. Pontes A, Zhang Y, Hu W. Novel functions of GABA signaling in adult neurogenesis. Front Biol (Beijing) 2013;8.
44. Berg DA, Belnoue L, Song H, Simon A. Neurotransmitter-mediated control of neurogenesis in the adult vertebrate brain. Development 2013;140:2548-61.
45. Pohl SG, Brook N, Agostino M, Arfuso F, Kumar AP, et al. Wnt signaling in triple-negative breast cancer. Oncogenesis 2017;6:e310.
46. Bilir B, Kucuk O, Moreno CS. Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells. J Transl Med 2013;11:280.
